Anti-SLAMF6 decreased the number of CLL cells everywhere except in peritoneal cavity and Ibrutinib increased the efficiency of anti-SLAMF6 by inducing the release of CLL cells from their niche. The gene discussed is SLAMF6; the disease is B-cell chronic lymphocytic leukemia.